Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Roche Glycart Ag

Fujirebio Europe N.v.

Roche Molecular Systems, Inc.

F. Hoffmann-la Roche Ag

Innogenetics N.v.

Roche Gmbh

Thomas Emrich

Ekkehard Moessner

Hubert Kettenberger

Tilman Schlothauer

Guy Georges

Olaf Mundigl

Stefan Dengl

Michael Molhoj

Jens Niewoehner

Ulrich Goepfert

Joerg Moelleken

Fiona Grueninger

Adrian Hugenmatter

Kevin Brady

Pablo Umana

Ralf Hosse

Rudi Rossau

Anton Jochner

Gerd Haberhausen

Jens Fischer

Matthias Hinzpeter

Daigen Xu

Lydia Jasmin Duerner

Laurent Lariviere

Gregor Sagner

Geert Jannes

Michael Grol

Gudrun Schmitz-Agheguian

Hermann Leying

Wolfgang Richter

Thomas Kraft

Lia Verdoodt

Angela Schoch

Sofie Claeys

Gerlinde Karl

Martin Moczko

Hilde De Henau

Joachim Van Crombruggen

Wouter Mijs

Daniel De Vos

Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.

Vitro prediction of in vivo half-life

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.

Antibody selection method

Humanized anti-Tau(pS422) antibodies and methods of use

Humanized anti-tau(pS422) antibodies and methods of use

The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Interleukin-10 fusion proteins and uses thereof

Interleukin-10 fusion proteins

The present invention relates to a method for the specific detection and/or identification ofspecies, in particularand/or, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification ofspecies, in particular ofand/or, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region ofspecies in a sample.

Detection, identification and differentiation of eubacterial taxa using a hybridization assay

The present invention relates to a method for the specific detection and/or identification ofspecies, in particular, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification ofspecies, in particular of, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region ofspecies in a sample.

[object Object]

The present invention is related to a method for detecting a target biomolecule in test sample by adding an internal control biomolecule to the test sample; to a negative control sample, to a positive control sample and to a reagent control sample or adding an internal control biomolecule to the test sample, to a negative control sample, to a positive control sample comprising the target biomolecule and providing a reagent control sample comprising the target biomolecule, determining in each sample a signal, and verifying the signal thereby detecting the target biomolecule. The invention is also related to a method for verifying the determination of a signal indicating the presence of a target biomolecule. The invention is further related to a method for detecting the presence or the absence of a member of a group of target nucleic acids in a sample and a method for verifying the determination of a signal indicating the presence of a member of a group of target nucleic acids.

Control for nucleic acid testing

The invention concerns monoclonal antibodies against the epitope YPYDVPDYA (SEQ ID NO: 1) which is derived from the haemagglutinin of the human influenza virus and are suitable for the detection and isolation of native haemagglutinin of the human influenza virus, of modified haemagglutinin or of haemagglutinin fusion proteins and have an affinity of &#x3e;10M, in particular of 10to 10M.

Monoclonal antibodies against the epitope YPYDVPDYA, a process for their production and their use

Method of detecting telomerase activity

Growing community of inventors

Iffeldorf, Germany

Thomas Emrich